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Abstract
Migraine affects the daily life of millions of people around the world. The most 
well-known disabling symptom associated with this illness is the intense headache. 
Nowadays, there are treatments that can diminish the level of pain.
OnabotulinumtoxinA (BoNT-A) has become a very popular medication for treating 
migraine headaches in those cases in which other medication is not working, 
typically in chronic migraines. Currently, the positive response to Botox treatment 
is not clearly understood, yet understanding the mechanisms that determine the 
effectiveness of the treatment could help with the development of more effective 
treatments.
To solve this problem, this paper sets up a realistic scenario of electronic medical 
records of migraineurs under BoNT-A treatment where some clinical features from 
real patients are labeled by doctors. Medical registers have been preprocessed. 
A label encoding method based on simulated annealing has been proposed. Two 
methodologies for predicting the results of the first and the second infiltration of the .e01043
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HIT6 metric is described, which achieves an accuracy over 91%. Secondly, when 
this value is not available, several classifiers and clustering methods have been 
performed in order to predict the reduction and adverse effects, obtaining an accuracy 
of 85%. Some clinical features as Greater occipital nerves (GON), chronic migraine 
time evolution and others have been detected as relevant features when examining 
the prediction models. The GON and the retroocular component have also been 
described as important features according to doctors.
Keywords: Computer science, Neurology, Bioinformatics, Medicine
1. Introduction
Migraine is a common neurological disorder characterized by recurrent headaches. 
Migraine attacks usually last for 4-72 h and involve moderate or severe intensity 
headaches which typically are worsened by routine physical activity, are of a 
pulsating nature, and are associated with nausea, vomiting, photophobia or
phonophobia [1]. In clinical terms, migraine can be classified into two types 
according to the frequency of pain: episodic migraine (less frequent headaches) 
and chronic migraine. Chronic migraine is defined as a headache occurring on 15 
or more days per month for more than 3 months, and which has the features of a 
migraine headache on at least 8 days per month [1]. Globally, approximately 2% 
of the population experiences chronic migraine [2]. In addition to the increased 
use of analgesic medication, visits to doctors, and visits to the emergency services, 
chronic migraine has a high socioeconomic cost, with higher direct and indirect 
costs. Furthermore, chronic migraine sufferers are more prone to anxiety, depression, 
other chronic diseases (respiratory, heart or circulatory) and more chronic pain, all 
of this associated with significant personal, societal, and economic burdens [3,4].
The pharmacological treatment of chronic migraine is based on two pillars: abortive 
treatment of acute migraine attacks (that taken only in the acute pain phase) and 
preventive therapy. The latter is used to diminish the severity, frequency or duration 
of attacks. Preventive therapy includes additional benefits such as reduction of 
disability and enhancement of response to acute treatments [5]. It may also result 
in a reduction in health care costs [6].
Many classes of medication are used for migraine prevention: antiepileptic drugs, 
antidepressants, betablockers, calcium channel antagonists, serotonin antagonists, 
and botulinum neurotoxins, among others. In the case of chronic migraine, although 
all preventive treatments for migraine may be useful, only topiramate (a type of 
antiepileptic) and OnabotulinumtoxinA (BoNT-A) [7] have solid proven evidence 
for their use [8,9,10,11,12,13]. BoNT-A has been an extended use treatment for on.2018.e01043
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in the United States (FDA), having also shown a more sustained effect and better 
tolerability than topiramate in the few comparative studies performed [14,15]. 
BoNT-A can be injected under the skin (subcutaneous) or inside the muscles 
(intramuscular) in accordance with the so-called The Phase III REsearch Evaluating 
Migraine Prophylaxis Therapy (PREEMPT) paradigm. This injection method 
consists of using both fixed and follow-the-pain sites, with additional specific 
follow-the-pain sites considered depending on individual symptoms. This procedure 
should be carried out in repeated patterns after several months. Following the 
results of the initial clinical trials and subsequent published studies in real-life 
settings [16,17,18,19], today it is known that 70-80% of patients with chronic 
migraine show an improvement with this treatment (improvement defined as a 
reduction in migraine attack frequency or days with attacks by at least 50% within 3 
months, leading to a significantly improved functioning of the patients and their 
overall quality of life). Moreover, there is evidence that patients with chronic 
migraine who do not show the desired treatment response after the first cycle of 
BoNT-A treatment may indeed experience clinical improvement after one or two 
additional treatment cycles [20].
However, in clinical practice, about 20-30% of chronic migraineurs do not respond 
to BoNT-A. One of the most debated aspects in recent years has been the possible 
relationship between the clinical phenotype of migraine attacks and the response to 
BoNT-A. As has been mentioned in certain publications [21], it is very important 
to predict if the BoNT-A treatment will be effective in a patient. Knowing the 
phenotype-response relationship may help in the development of new treatments for 
the 20-30% of patients that do not respond to the treatment. Besides the cost, it would 
avoid the patients suffering the pain associated with the treatment.
In a real scenario of electronic medical records of migraineurs, we present a 
methodology for predicting whether or not the BoNT-A treatment will be efficient. 
Starting from the raw database provided by doctors, we preprocess it, identify the 
most promising feature to predict and then run several algorithms in order to get the 
prediction. Results show that it is possible to get an accuracy higher than 91% when 
employing the HIT6 [22] metric and 85% when this metric is missing. Moreover, 
our results show that some of the features leading to these accuracies are actually 
coherent with respect to the medical literature.
The rest of the paper is organized as follows. Section 2 describes the work related 
with some techniques applied to migraine and other illnesses. In Section 3, our 
methodology for predicting treatment results is explained. Section 4 describes the 
experiments and comparisons between different algorithms and our solution. Finally, 
our conclusions and future lines of work are presented in Section 5.on.2018.e01043
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Several studies have looked at the clinical features of patients with migraine 
which may be associated with a favorable response to BoNT-A treatment, although 
conclusive results are not yet available for use in clinical practice. Possible predictors 
of a good response have been proposed: allodynia (painful hypersensitivity to 
superficial stimuli) [23], the unilateral character of a migraine [23,24], associated 
migraine aura (visual, language, motor or sensory alterations occurring prior to 
pain) [25], or the build-up time to maximum pain (shorter time, better response to 
BoNT-A) [26]. Pain directionality also seems to be a possible clinical predictor. This 
feature refers to whether the headache feels like it is exploding, imploding or ocular. 
The term exploding refers to when the discomfort is felt pushing from the inside 
out. Patients suffering from imploding or ocular pain tend to be relieved with the 
BoNT-A treatment than those with the exploding [27]. Pagola et al. studied a number 
of possible clinical predictive features in parallel, including unilateral location of 
headache, pericranial muscular tension, directionality of pain, duration of migraine 
history and medication overuse, comparing responders to BoNT-A treatment with 
non-responders, but no significant differences emerged [28].
In order to find the most significant features of patients and classify them, there is a 
vast number of algorithms available [29]. C4.5, k-means, Support Vector Machines 
(SVM), Expectation-Maximization (EM) algorithm, PageRank, AdaBoost, k-NN, 
Naive Bayes, and CART are among the most common data mining algorithms 
used by the research community in many fields. A Feature Subset Selection 
(FSS) approach is typically applied first [30] in order to improve the accuracy 
of the classifiers. This approach has certain advantages, such as offering a better 
understanding of the prediction model or a better generalization by reducing 
overfitting. This problem happens when a prediction model is very closely adjusted to 
the training data, so it does not perform well when predicting new observations [31]. 
These methods have been applied to different neurological anomalies, for example: 
a feature extraction and selection from EEG signals in combination with a sleep 
stages classifier [32], an automatic seizure detection system for newborns [33], or 
to assess the feasibility of employing accelerometers to characterize the postural 
behavior of early Parkinson’s disease subjects [34]. Furthermore, in order to improve 
migraine treatment predictions, we consider that simulated annealing (SA) [35]
is a particularly interesting approach to take into account. SA is a stochastic, 
metaheuristic technique used in difficult optimization problems to approximate the 
global optimum of a given function in its search space. This approach has been 
widely employed to improve the performance of other algorithms. For example, 
SA has been used to improve FSS in [36]. Furthermore, SVM and SA have been 
combined to find the best selected features to increase the accuracy of anomaly 
intrusion detection in [37], and for a hepatitis diagnosis method in [38].on.2018.e01043
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A key point to mention is how to measure the impact headaches have on daily life. 
In this sense, an important metric that allows the measurement of this issue is HIT6. 
The HIT6 [22] scale is a perceptional survey that is filled out by patients in order 
to measure their level of pain related with the migraine. In regular clinical practice, 
BoNT-A response is considered successful by doctors if it reduces migraine attack 
frequency or days with attacks by at least 50% within 3 months. Response features 
such as the HIT6 score (Headache Impact Test) are reflected less consistently. Thus, 
in our study, where data were obtained retrospectively through the review of clinical 
histories, we were able to obtain only a small set of patients for whom the HIT6 
score had been collected. As a consequence, for the vast majority of the cases we 
must define an alternative way to determine the efficiency of the BoNT-A based 
treatment.
Therefore, although there is an ongoing research into the prediction of the appearance 
of migraines and even the effects of migraine treatment, to the best of our knowledge 
there is no existing method for predicting the efficiency of the BoNT-A treatment. 
For this purpose, we propose two methodologies that are customized for the migraine 
patients’ clinical data, and which are able to deal with incomplete as well as 
heterogeneous data. Firstly, we present an approach that considers the medical HIT6 
metric in order to predict the treatment success. Secondly, as this metric is rarely 
found in our medical databases, an alternative approach that uses SA in combination 
with classification and clustering methods is presented.
3. Methodology
The issues involved in predicting the reduction of migraine symptoms when using 
the BoNT-A treatment will be described in this section. Figure 1 presents the 
framework on which this paper is based. Firstly, a database is loaded with the on.2018.e01043
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is selected by considering the limitations of the medical records. Thirdly, clinical 
features are categorized in order to work with homogeneous data. Afterwards, a 
feature weighting mechanism based on simulated annealing or a FSS step is applied 
for improving the prediction accuracy. Finally, different classification algorithms are 
run and the best models are analyzed in order to detect clinical features that allow to 
predict the effectiveness of the treatment.
3.1. Clinical data
The data were collected retrospectively from the review of medical histories of 
patients with chronic migraine and under previous or current treatment with BoNT-
A with follow-up at the Headache unit of two tertiary-level hospitals. To this end, the 
approval of the ethics committee of both hospitals was obtained under the documents 
ANA-TOX-2015-1 and PI-17-832 which are provided as supplementary content.
A total of 173 patients were included (116 from Hospital Clínico Universitario in 
Valladolid and 57 from Hospital Universitario de La Princesa, in Madrid). Sixty-two 
baseline features were categorized. It is necessary to mention that attributes, features, 
factors and variables are synonym terms in general. These features were related 
to the following points: clinical pain features, demographic features of patients, 
comorbidities, tested and concomitant preventive drugs, pain impact measures, and 
available analytical parameters. The latter were obtained from blood tests recorded 
in the clinical history which were performed for other reasons in the 3 months prior 
to, or 3 months after, the first infiltration, and included hemogram and liver, renal, 
thyroid, ferric, vitamin B12, folic acid and vitamin D profiles. The efficacy of BoNT-
A was evaluated by comparing the baseline situation (before the first infiltration) 
and the situation after 12-16 weeks following each of the infiltrations, through the 
following parameters: number of days of pain per month, percentage reduction in 
days with pain, subjective intensity of pain, number of days of disability due to 
pain per month, HIT-6 scale score, drug consumption for pain and adverse effects of 
infiltration. Since this was a retrospective study, not all the data could be obtained 
for each patient in a systematic way.
Only 18 out of 173 records contained the perceptional HIT6 value before infiltrations, 
and only 12 and 3 contain this value after the first and second BoNT-A infiltrations, 
respectively. On the other hand, we found several efficiency indicators such as the 
reduction and adverse effects, which are provided in 102 and 86 registers for the first 
and second infiltrations, respectively.
To tackle classification and prediction for migraine treatment with BoNT-A, clinical 
data need to be previously processed in order to achieve a high level of accuracy. In on.2018.e01043
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Toxin-age of onset 
(years)
Body mass index 
(kg/m𝟐)
Hemoglobin 
(g/dL)
Creatinine 
(mg/dL)
Platelets 
(u/mcL)
Reduction effects 
(1-4)
51 20.39 13.4 0.71 213000 4
49 26.5 14.2 0.55 252000 2
36 23.15 13.5 0.44 304000 3
26 17.7 13.1 0.66 218000 2
31 NA 14.8 0.71 327000 1
50 NA 16.2 0.74 327000 3
fact, some patients are non-respondent, while others respond after the 𝑖th session. 
In order to predict the patients’ behavior after the infiltrations, it is necessary to 
explore the patients’ data before these take place. In other words, in order to predict 
the outcome after the 𝑖th session, the clinical data of the patient as well as the 
outcome after the (𝑖 − 1)th infiltration are required. Nevertheless, some problems 
are encountered while evaluating these data. For example, a small set of patients 
with many features is typically present in our medical databases. In addition, the 
incompleteness of data is another problem that must be dealt with. Some features are 
given as continuous numeric values while other features are categorized by medics. 
All in all, it is hard to properly process all this information. As a consequence of 
these heterogeneous data, algorithms cannot infer a good model for predicting the 
outcome of the treatment. An example of these features can be observed in Table 1.
3.2. Class attribute selection
In order to estimate the goodness of the solutions, it is necessary to define a metric, 
class attribute, that indicates how efficient the infiltration has been. In other words, 
class attribute is the selected clinical feature used to measure the effectiveness 
of treatment. According to doctors, some clinical features such as HIT6, effects 
reduction, adverse effects, or days with headache are good candidates for class 
attributes. The main problem is that the values of these features are not usually 
provided, with the exception of reduction and adverse effects. In this section, we first 
discuss the HIT6 value, which obtained a high level of accuracy in the experiments, 
as well as its limitations. In addition, a class attribute based on both the reduction 
and adverse effects is proposed to tackle the limitations imposed by the use of HIT6.
3.2.1. HIT6
HIT6 is a highly specific perceptional value provided by doctors in order to measure 
the level of pain associated with migraine episodes. This value is obtained after 
patients fill out a standardized survey [22] consisting of six questions that capture on.2018.e01043
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never rarely sometimes very often always
Question 1 X
Question 2 X
Question 3 X
Question 4 X
Question 5 X
Question 6 X
Points added 6+6=12 8 10 11 13
the impact of headaches as well as their treatment. An example is shown in Table 2. 
These questions are:
1) When you have headaches, how often is the pain severe?
2) How often do headaches limit your ability to perform usual daily activities 
including housework, your job, homework, or social activities?
3) When you have a headache, how often do you wish you could lie down?
4) In the past 4 weeks, how often have you felt too tired to do work or daily activities 
because of your headaches?
5) In the past 4 weeks, how often have you felt fed up or irritated because of your 
headaches?
6) In the past 4 weeks, how often did headaches limit your ability to concentrate 
on work or daily activities?
The values allowed for the answers are: never, rarely, sometimes, very often, and 
always. These values are graded with 6, 8, 10, 11 and 13 points, respectively. The 
HIT6 value is computed as the sum of all the individual scores. If the HIT6 value is 
50 or higher, doctors interpret that the level of pain is enough to affect quality of life.
As this metric is perceptional, we have focused only on those database records 
containing the HIT6 value prior and after the infiltration. By defining the class 
attribute as the difference between the two values, as Equation (1) indicates, the 
bias due to different perceptions from different patients is diminished. According 
to [20], if the HIT6 value after the infiltration diminishes by more than 30%, the 
treatment is considered as successful, and unsuccessful otherwise. Hence, for this 
particular class attribute, only two categories have been defined, namely: successful 
and unsuccessful.
The HIT6 values are rarely found in clinical databases. In fact, only 12 patients from 
the clinical dataset from Hospital Universitario de La Princesa and Hospital Clínico 
Universitario de Valladolid had the HIT6 value before and after the first infiltration on.2018.e01043
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experiments section, another class attribute must be defined to tackle other cases.
𝐻𝐼𝑇 6𝑑𝑖𝑓 = 𝐻𝐼𝑇 6𝑏 −𝐻𝐼𝑇 6𝑎 . (1)
3.2.2. Reduction and adverse effects
As a consequence of the HIT6 value being missing in many clinical records, the 
reduction (R) and the adverse (A) effects, which are more frequently found in the 
databases, have been selected to define the class attribute. Reduction and adverse 
effects are defined with values directly provided by doctors. These clinical features 
are quantified from 1 to 4, using 1 for the lowest and 4 for the highest level of effects.
R and A are measurable values from an objective point of view based on definitions. 
R is a clinical objective value categorized from 1 to 4 according to the percentage 
of reduction of days of migraine, being 1 when the percentage reduction of days 
of migraine is less than or equal to 25%, 2 for the interval between 25% and 49%, 
3 for the interval between 50% and 74% and 4 when the percentage is greater than 
or equal to 75%. A is equal to 1 when there are no adverse effects, 2 when there 
are mild adverse effects (easily tolerated), 3 when there are moderate adverse effects 
(interfere with usual activities and may require suspension of treatment) and 4 when 
there are serious adverse effects (incapacitate or disable usual activities, and require 
suspension of treatment as well as medical intervention).
A high level of R indicates good treatment results, while high levels of A point to 
many adverse effects. Hence, in order to obtain a directly proportional feature, our 
class attribute (𝑁𝐴𝐶 ) has been determined by dividing R and A, as Equation (2)
shows.
𝑁𝐴𝐶 =
𝑅
𝐴
. (2)
In this work, a similar approach to the one based on HIT6 (two response categories: 
low and high) [20] has been considered for class attribute categorization, instead of 
the three categories (low, medium and high) used for the rest of the clinical features. 
In following this approach, two intervals (low and high) need to be defined before 
trying to predict the efficiency of the treatment when using 𝑁𝐴𝐶 as class attribute.
Table 3 depicts an instance of the 𝑁𝐴𝐶 computation using different values provided 
by the hospitals. Lower responses are labeled when the 𝑁𝐴𝐶 value falls into the 
(𝑉𝑚𝑖𝑛, cut-off point) interval, while high response labels are used for those values 
falling within the (cut-off point, 𝑉𝑚𝑎𝑥) interval. In this case, 𝑉𝑚𝑖𝑛 = 0.25 occurs 
when 𝑅 = 1 and 𝐴 = 4, while 𝑉𝑚𝑎𝑥 = 4 occurs when 𝑅 = 4 and 𝐴 = 1. We 
select a cut-off point of 1.40. The reason to use this value is the fact of trying to on.2018.e01043
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Reduction effects (R) Adverse effects (A) R/A Categorized value
1 1 1 low
2 1 2 high
3 2 1.5 high
1 2 0.5 low
emulate the criterion used of the 30% decrease in the HIT6 value. It is considered 
as an effective response to the treatment in the PREEMPT clinical trial [20]. In this 
way, values lower than 1.40 represent the 30% of the values that 𝑁𝐴𝐶 can take. Then, 
the low and high categories are defined with the intervals (0.25, 1.40) and (1.40, 4), 
respectively.
3.3. Preprocessing
3.3.1. Categorization of clinical features
In order to improve prediction accuracy for the BoNT-A treatment, the heterogeneous 
data from the hospitals is first categorized. The method selected for the categorization 
of our medical data is based on the mean and standard deviation. Applying this 
method makes it possible to work with more homogeneous values.
The mean and standard deviation categorization type centers the intervals around 
the mean (𝜇), and defines subsequent intervals by adding or subtracting the standard 
deviation (𝜎). For instance, if three categories are defined for a certain clinical 
feature, the intervals (𝑉𝑚𝑖𝑛, 𝜇 − 𝜎), (𝜇 − 𝜎, 𝜇 + 𝜎) and (𝜇 + 𝜎, 𝑉𝑚𝑎𝑥) are used to 
refer to value 1, value 2 and value 3, respectively. It should be noted that 𝑉𝑚𝑖𝑛 and 
𝑉𝑚𝑎𝑥 are the minimum and maximum values of the data, respectively. By following 
a similar strategy it is possible to define multiple intervals. The pseudocode of the 
intervals generation for a feature categorization is presented in Algorithm 1.
3.3.2. Feature subset selection (FSS)
This technique makes it possible to enhance the prediction efficiency of the 
classification and clustering methods, as it just considers the most influential features 
when predicting the class attribute value. This approach has certain advantages, such 
as offering a better understanding of the prediction model and a better generalization 
by reducing overfitting [39]. Several approaches have been designed to implement 
the FSS technique as the filter, wrapper or embedded method [40]. The filter 
type method selects features without considering the model. In this approach, the 
emphasis is placed on the general features such as the existent correlation with the 
class to predict. The wrapper method tries to find interactions between features by on.2018.e01043
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FSS type Feature evalu
FSS1 CfsSubsetEval
FSS2 WrapperSubsetE
FSS3 ChiSquaredAttri
FSS4 ClassifierSubsetE
11 https://doi.org/10.1016/j.heliy
2405-8440/© 2019 The Authors. PubAlgorithm 1: Intervals for categorizing features
Require: Number of intervals 𝑁 , mean 𝜇 and standard deviation 𝜎. An empty list of intervals 𝐼 = ∅.
1: if 𝑁 = 1 then
2: 𝐼 =
{
(𝑉𝑚𝑖𝑛, 𝑉𝑚𝑎𝑥)
}
3: end if
4: if 𝑁 = 2 then
5: 𝐼 =
{
(𝑉𝑚𝑖𝑛, 𝜇), (𝜇, 𝑉𝑚𝑎𝑥)
}
6: end if
7: if 𝑁 ≥ 3 then
8: if isOdd(𝑁) then
9: 𝐼 = {(𝜇 − 𝜎, 𝜇 + 𝜎)}
10: 𝜆 = 𝑁−12
11: else
12: 𝐼 = {(𝜇 − 𝜎, 𝜇), (𝜇, 𝜇 + 𝜎)}
13: 𝜆 = 𝑁−22
14: end if
15: 𝐼− =
{
(𝑉𝑚𝑖𝑛, 𝜇 − 𝜆𝜎)
}
16: 𝐼+ =
{
(𝜇 + 𝜆𝜎, 𝑉𝑚𝑎𝑥)
}
17: for 𝑗 = 𝜆 − 1 downto 1 do
18: 𝐼− = 𝐼− ∪ {(𝜇 − (𝑗 + 1)𝜎, 𝜇 − 𝑗𝜎)}
19: 𝐼+ = 𝐼+ ∪ {(𝜇 + 𝑗𝜎, 𝜇 + (𝑗 + 1)𝜎)}
20: end for
21: 𝐼 = 𝐼 ∪ 𝐼− ∪ 𝐼+
22: sort(𝐼)
23: end if
24: return 𝐼
methods used in experiments.
ator Description Search method
Evaluates the worth of a subset of features by considering the individual 
predictive ability of each feature along with the degree of redundancy 
between them.
BestFirst
val Evaluates feature sets by using a learning scheme. BestFirst
buteEval Evaluates the worth of a feature by computing the value of the 
chi-squared statistic with respect to the class.
Ranker
val Evaluates feature subsets on training data or a separate hold out testing 
set.
BestFirst
evaluating subsets of them. Finally, the embedded method considers certain search 
algorithms in order to combine the advantages of the first two methods.
Different FSS algorithms [30] have been applied in order to determine the most 
relevant clinical features when obtaining the treatment response prediction. Table 4
shows the main features of the four studied FSS implementations, namely: feature 
evaluator and search method. C4.5 is the classifier selected to work together with the 
WrapperSubsetEval and ClassifierSubsetEval methods to measure the worthiness of 
the subset of features within the dataset.on.2018.e01043
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3.3.3. Weighting features
In order to enhance the accuracy of the classification and the clustering algorithms, 
the simulated annealing method (SA) [35] has also been considered as a
preprocessing step. SA is a randomized search method for optimization. Our purpose 
is to find those weights that allow us to do improvements in the representation of the 
numeric labels encoded by doctors for each infiltration.
When applying this method to our problem, we define the error (100% - accuracy) 
as the objective value to be diminished. In this way, the SA algorithm will be able to 
optimize a weighted sum of features. The approach has been implemented using the 
Hero library [41]. This library implements the “Natural Optimization” proposed by 
De Vicente et al. [42], which means that the temperature does not need to be given 
because it is continuously tuned while running the SA algorithm (Equation (3)). In 
addition, an initial random weight vector solution (one weight per attribute) will be 
given as input to the SA algorithm. After this, the error rate will be computed and 
saved as the initial fitness value to be minimized. Then, a mutation over one of the 
weights will be performed. The procedure will be repeated until completing a defined 
maximum number of iterations (𝑁).
Figure 2 depicts a flowchart with the methodology, where 𝑇 is defined by Equation 
(3)
𝑇 =
𝐾 × (𝐶𝑚𝑖𝑛 − 𝐶𝑖𝑛𝑖𝑡)
, (3)
𝑁
on.2018.e01043
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degree and time/quality trade-off and has been set to 1, and 𝐶𝑚𝑖𝑛 and 𝐶𝑖𝑛𝑖𝑡 refer to the 
current minimal cost and initial cost, respectively. The energy difference is defined 
in Equation (4).
𝐸𝑑𝑖𝑓𝑓 = 𝐶𝑠𝑜𝑙 − 𝐶𝑚𝑖𝑛 , (4)
where 𝐶𝑠𝑜𝑙 is the cost of the solution. Finally, the probability (𝑃 ) to compare with 
the random number (𝑅) is given by Equation (5). 𝑃 is the probability of changing to 
a new solution. This is calculated when accuracy is not lower than the fitness value. 
When 𝑅 ≤ 𝑃 , SA moves the solution to another point within the search space to 
avoid being trapped in a local minimum.
𝑃 = 𝑒(−𝐸𝑑𝑖𝑓𝑓 ∕𝑇 ) . (5)
3.4. Prediction accuracy evaluation
3.4.1. Classification
The problem of prediction could be tackled by using classification algorithms which 
identify categories for new records based on the previous data (training dataset) [39]. 
These records (observations) have been previously labeled by doctors (supervised 
learning). This implies that given N records characterized by given prediction 
features, the training data will be transformed into a classification model able to 
predict the label of the class attribute for every new record with some level of success 
(accuracy).
In our particular case, the 𝑁𝐴𝐶 class attribute is used whenever the HIT6 value is not 
available (for the majority of the patients). Several state-of-the-art classifiers [29]
(e.g. TAN, RIPPER, C4.5 or NB tree algorithms) are applied in order to compare 
their prediction accuracy and to gain a general idea of possible ways to improve the 
results. All these algorithms and its parameters are described in Table 5.
3.4.2. Clustering
This technique works by grouping all the records or observations into different 
groups called “clusters”, each of them containing elements with similar features [39]. 
In our study, we have considered two different clusters (low and high) to indicate 
the result of the treatment. In this technique, we consider 𝑁𝐴𝐶 as the class attribute. 
Different state-of-the-art clustering algorithms such as k-means, expectation-
maximization (𝐸𝑀) and farthest-first have been selected to predict treatment 
response. The clustering algorithm is usually an unsupervised method. However, the on.2018.e01043
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Table 5. Descriptions of clas
Classification algorithm
Naive Bayes N
a
IBk k
RIPPER P
to
C4.5 G
Logistic B
w
AdaBoostM1 M
Bagging M
LMT B
a
NBTree G
th
Random forest B
Random tree B
e
REPTree B
a
DecisionStump B
ju
SVM B
o
c
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Description Parameters
umeric estimator precision values are chosen based on 
nalysis of the training data.
No parameters
-nearest neighbors classifier. k-NN=2, Linear Search algorithm
ropositional rule learner, Repeated Incremental Pruning 
 Produce Error Reduction.
Pruning=true, Seed=1
enerates a pruned or unpruned C4.5 decision tree. Confidence factor=0.25, Seed=1
uilds and uses a multinomial logistic regression model 
ith a ridge estimator.
maxIts=-1, Ridge=1 ⋅ 10−8
eta classifier: Boosts a nominal class classifier. Classifier=Decision Stump, Iterations=10, 
Seed=1
eta classifier: Bagging a classifier to reduce variance. bagSizePercent=100, Classifier=Random 
tree or C4.5, Iterations=10, Seed=1
uilds classification trees with logistic regression functions 
t the leaves.
minNumInstances=15, 
numBoostingIterations=-1
enerates a decision tree using Naive Bayes classifiers for 
e leaves.
No parameters
uilds a forest of random trees. Number of trees=100, Seed=1
uilds a tree considering K randomly chosen features for 
ach node. Performs no pruning.
minNum=1, Seed=1
uilds a regression(decision) tree using information gain 
nd variance and prunes it using reduced-error pruning.
maxDepth=-1, minNum=2
uilds a tree that make predictions based on the value of 
st a single input feature (also called 1-rules).
No parameters
uilds a model that assigns new examples to one category 
r the other, making it a non-probabilistic binary linear 
lassifier.
cacheSize=40, cost=1, kernelType=radial
values of the class attribute have been tagged. Additionally, two clusters have been 
defined to categorize responses to treatment, so we will use the cluster algorithms as 
supervised clustering. In this sense, the clustering algorithm is applied to classified 
examples and has the objective of identifying clusters that have a high probability 
density with respect to a single class. As mentioned by Eick et al. (2005) [43], 
the fitness functions used for supervised clustering are significantly different from 
the fitness functions used by traditional clustering algorithms. The fitness function 
evaluates a clustering based on the number of clusters and class impurity. The 
impurity refers to measure the percentage of minority examples in the different 
clusters of a determined cluster.
In addition, a majority voting metacluster composed of the three aforementioned 
algorithms has also been considered. Hence, the result of the metacluster will be the 
dominant value among the three clustering algorithms. An example of this behavior 
is presented in Table 6.
3.5. Consensus model
As was mentioned in Section 1, the pathophysiological features that determine the 
positive or negative response to the migraine treatment are not known yet [44]. We on.2018.e01043
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EM k-means Farthest-First Predicted value
low high low low
high low high high
low high high high
low low high low
can take advantage of the use of a consensus model to reveal these features. The 
idea is not to build a consensus predictor model, but to understand the most relevant 
clinical features that exist in the majority of the induced prediction models of the 
best classifier.
Ensemble techniques can help us analyze feature relations with the construction 
of consensus models to make new and relevant findings [45,46]. In this sense, 
Armañanzas et al. [47] have proposed an ensemble interaction network for unveiling 
biological relations when analyzing Alzheimer’s disease. In that study, many 
Bayesian k-dependence models are induced to output a gene interaction network 
composed of arcs (edges). An occurrence threshold t is defined to output the most 
frequent edges above a predefined confidence level (the 0.999 quantile is used in 
order to retain just the most important connections). The list of interaction networks 
and the associated list of highly relevant features are obtained to reveal or corroborate 
biological hypotheses in this disease. Other studies [48,49] can be found in the 
literature with similar purposes.
In this paper, this technique is applied in order to group different prediction models 
(decision trees) produced by the best classifier in terms of accuracy for both 
infiltrations. This is done with the purpose of finding explicit features and relations 
between medical features that influence the treatment response prediction. In the 
FSS method (Section 3.3.2), these features are selected before the construction of the 
prediction model by using different metrics. In the ensemble interaction network, the 
idea is to invert the feature selection process of FSS, which means that the relevant 
features will be selected after, and not before, the construction of the prediction 
models.
We define the decision tree model as the graph 𝐺(𝑉 , 𝐸), where 𝑉 represents the 
vertex list (features as vertices) of the model and 𝐸 represents the list of edges 
(relations between vertices) of the model. The interactions in the decision tree consist 
of parent-child edge relations. Nodes are filled with the feature values and edges 
represent the parent-child relation from the decision tree model. Edges for the first 
level of the induced models will have a null value as vertex 𝑢 in the edge tuple (𝑢, 𝑣)
because the roots of decision trees do not have parents. Many decision trees will 
be induced by a resampling method (k-fold cross validation) together with the SA 
optimization. For each level of the decision tree, the most frequent clinical features 
will be taken into account. After this, an interaction network will be depicted with on.2018.e01043
lished by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Article No~e01043
16 https://doi.org/10.1016/j.heliy
2405-8440/© 2019 The Authors. Pubedges whose frequencies are higher than a reliability threshold t. Edges occurring 
more than t times for each level of the tree will be retained. After that, these relevant 
features will be contrasted with the most important features obtained with the FSS 
methodology.
The threshold value t will be different for each level of the tree. Edges will be sorted 
according to their frequency of appearance in a given level. In order to retain only one 
vertex as root of the consensus decision tree, we will retrieve only the 0.99 quantile 
(t value) for the first level of edges of the induced models. For the rest of the levels, 
the 0.9 quantile will determine the t value for retaining the most important edges. 
These quantile values have been defined by considering the 0.999 quantile applied 
by Armañanzas et al. [47] but modified with the purpose of retaining only one root 
and multiple important child nodes in the consensus decision tree proposed. All these 
steps are summarized in Algorithm 2. Table 7 presents the functions and definition 
of variables used in the algorithm.
Algorithm 2: Relevant features in consensus trees
Require: Lists 𝑋1,…,𝐿𝑚𝑎𝑥 and 𝐿𝑚𝑎𝑥.
1: 𝑖 = 1 and 𝑀 = ∅
2: 𝑡=tvalue(0.99, 𝑋1)
3: while 𝑋1 ≠ ∅ do
4: 𝑒(𝑢, 𝑣)=head(𝑋1)
5: if 𝑤(𝑒, 𝑋1) ≥ 𝑡 then
6: add(𝑒, 𝑀)
7: end if
8: end while
9: for 𝑖 = 2, 𝑖 < 𝐿𝑚𝑎𝑥, 𝑖++ do
10: 𝑡=tvalue(0.9, 𝑋𝑖)
11: while 𝑋𝑖 ≠ ∅ do
12: 𝑒(𝑢, 𝑣)=head(𝑋𝑖)
13: if 𝑤(𝑒, 𝑋𝑖) ≥ 𝑡 and ∃𝑒′ = (𝑢′, 𝑣′) ∈ 𝑀 ∶ 𝑢 = 𝑣′ then
14: add(𝑒, 𝑀)
15: end if
16: end while
17: end for
18: return 𝑀
4. Experimental
In order to test the proposals, our framework was implemented with Java and using 
the Hero library [41] as well as Weka 3.8 [50]. As was mentioned in Section 3.1, the 
clinical dataset consists of 102 patients that have undergone the first infiltration and 
86 the second infiltration during BoNT-A treatment. These records are divided into on.2018.e01043
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Name Description
𝑣 Vertex or node.
𝑒(𝑢, 𝑣) Edge 𝑢 → 𝑣, where 𝑢 is parent of 𝑣.
𝑤(𝑒,𝑋𝑖) Weight of an edge e. 𝑤(𝑒, 𝑋𝑖) = |{𝑒 ∈ 𝑋𝑖}|.
𝑋𝑖 The edges list at level 𝑖 of the induced prediction models (decision trees) for a given 
infiltration.
𝑀 List of nodes that conform the consensus tree.
𝐿𝑚𝑎𝑥 A defined maximum number of levels to explore for the consensus tree construction.
tvalue(𝑞, 𝑋) Calculates the 𝑡 value given the quantile (𝑞) value and the 𝑋 list.
head(𝑋) Returns and removes the first element of the 𝑋 list.
add(𝑒,X) Adds 𝑒 to the 𝑋 list.
two datasets for each infiltration, one for training-test and another for validation. For 
the first infiltration, 76 and 26 records were employed for the training-testing and the 
validation datasets, respectively. In the second infiltration, 64 and 22 records were 
used for the training-testing and the validation sets, respectively. When training-
testing the predictions over the class attribute, the k-fold cross validation (k=10) 
was applied without the use of a validation set [51]. The results presented in this 
section are based on the measured accuracy of the k-fold cross validation. The k-fold 
cross validation method has been used to avoid reporting overoptimistic results of 
classifier algorithms because of overfitting. The validation set was used to verify 
the results found by the k-fold cross validation process. Moreover, the k-fold cross 
validation results were used (as fitness value) to improve the SA parameter tuning 
process (feature weighting) in the experiment presented in Section 4.2.3. Clinical 
data were provided by the Hospital Clínico Universitario in Valladolid, and the 
Hospital Universitario de La Princesa in Madrid, both being in Spain.
4.1. HIT6 prediction
In this experiment, only the clinical data belonging to patients whose database 
record contains the HIT6 value were considered. The purpose is to predict high-
low differences in HIT6 values before and after infiltrations, as was explained in 
Section 3.2.1. The HIT6 value is required before and after the first infiltration with 
BoNT-A in order to apply Equation (1). Only 12 patients meet this requirement. In 
this initial test, the feature subset selection (FSS) step was not considered. Moreover, 
the validation dataset was not taken into account because of the number of records.
Due to the small size of the dataset with the HIT6 value, an exhaustive cross-
validation method called Leave-One-Out Cross-Validation (LOOCV) is applied 
for training-testing the classifier algorithms of this section. This method has been 
applied with the purpose of creating all possible partitions of 𝑛 cases, when the 
cardinality of a training set is fixed to 𝑛 − 1 and the cardinality of a testing set is 1.on.2018.e01043
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Classification algorithm First infiltration
Accuracy Sensitivity Specificity
Naive Bayes 66.66% 0.00 0.72
IBk 66.66% 0.00 0.72
RIPPER 75.00% 0.50 0.80
C4.5 91.66% 1.00 0.90
Logistic 50.00% 0.20 0.71
AdaBoostM1 (DecisionStump) 91.66% 1.00 0.90
Bagging (Random tree) 75.00% 0.50 0.80
Bagging (C4.5) 66.66% 0.00 0.72
LMT 58.33% 0.25 0.75
NBTree 91.66% 1.00 0.90
Random forest 75.00% 0.00 0.75
Random tree 66.66% 0.33 0.78
REPTree 75.00% 0.00 0.75
DecisionStump 91.66% 1.00 0.90
SVM 75.00% 0.00 0.75
Means 74.44% 0.39 0.79
Medians 75.00% 0.25 0.75
Table 8 presents the accuracy values after employing the class attribute defined by 
Equation (1) in combination with several state-of-the-art classification algorithms. 
As can be observed, some algorithms show a high level of accuracy. For example, the 
AdaBoost, DecisionStump, C4.5 and NB tree algorithms possess an accuracy that 
is higher than 91%. These algorithms are based on rules or trees, with the exception 
of the AdaBoost meta classifier algorithm, which boosts a nominal class classifier 
(DecisionStump).
The values of sensitivity and specificity are also presented in Table 8. These values 
are considered because they are more important than high accuracy values in many 
medical problems [52]. The sensitivity measures the fraction of positive cases that 
are classified as positive, while the specificity measures the fraction of negative cases 
classified as negative. In our case, the positive values will be the patients who have 
a good therapeutic response (labeled as “high”) to the treatment, while the negative 
cases will be the ones that obtain a bad response (labeled as “low”). Overall, the 
classifiers that obtain high accuracies (greater than 90%) also have high values of 
specificity and sensitivity. This means that the number of false positives and false 
negatives is very low.
Despite the positive results, there are very few patients possessing HIT6 values for 
the first infiltration (12 records). As it has been mentioned above, it is not usual to 
have this information in our clinical databases. In fact, predictions on the second 
infiltration have not been performed because only 3 patients registered their HIT6 
value after this infiltration. As a consequence of this reduced amount of records, we 
can only conclude that HIT6 seems to be a good choice as a measurement of the 
treatment effectiveness. Therefore, we can only recommend the collection of such on.2018.e01043
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Classification algorithm
Naive Bayes
IBk
RIPPER
C4.5
Logistic
AdaBoostM1 (DecisionStump
Bagging (Random tree)
Bagging (C4.5)
LMT
NBTree
Random forest
Random tree
REPTree
DecisionStump
SVM
Means
Medians
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First infiltration Second infiltration
Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity
57.89% 0.65 0.44 51.56% 0.50 0.53
50% 0.78 0.35 59.37% 0.61 0.58
56.57% 0.61 0.33 59.37% 0.60 0.59
50% 0.65 0.22 48.43% 0.46 0.50
51.31% 0.61 0.37 51.56% 0.50 0.53
) 53.94% 0.60 0.28 45.31% 0.41 0.48
50% 0.57 0.09 54.68% 0.54 0.55
43.42% 0.54 0.15 57.81% 0.58 0.57
63.15% 0.63 1.00 56.25% 0.56 0.56
51.31% 0.60 0.33 62.50% 0.61 0.64
55.26% 0.60 0.27 51.56% 0.50 0.53
50% 0.58 0.30 56.25% 0.55 0.58
57.89% 0.61 0.29 48.43% 0.44 0.50
59.21% 0.61 0.25 51.56% 0.50 0.52
61.84% 0.62 0.00 50.00% 0.48 0.51
54.12% 0.62 0.31 53.64% 0.52 0.54
53.94% 0.61 0.29 51.56% 0.50 0.53
clinical feature in the medical records of migraine treatment and more specifically in 
the treatment with BoNT-A. Future research may show that HIT6 is a good severity 
index for measuring the effectiveness in the migraine treatment. Consequently, other 
strategies for treatment classification need to be analyzed.
4.2. Reduction and adverse-effects-based prediction
Because of the lack of availability of HIT6 values, in this section the new class 
attribute defined by Equation (2) is considered. In the same fashion as defined in 
Section 3.2.2, the reduction-adverse effect values are used to measure the accuracy 
comparison among different classification and clustering algorithms of this section.
4.2.1. Classification methods
Several classifiers were applied in order to select the best algorithm in terms of 
accuracy. In Table 9, the accuracy percentage of different classifiers is presented. 
High values of sensitivity and specificity are also presented to visualize the correct 
prediction of high and low responses to treatment. Some algorithms achieved an 
accuracy of more than 60% for the two class values classification (high-low) on 
the first infiltration treatment prediction. By considering a probability function that 
predicts the two class values with a probability of 50% for each one, it can be 
observed that these algorithms do not achieve high accuracies. Moreover, 63.72% of 
class values in the complete dataset take the value of “high” as treatment response 
after the first infiltration. Therefore, classifying all instances as “high” can ensure on.2018.e01043
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Features selected FSS1 FSS2 FSS3 FSS4
Onset age of toxin treatment X
Retroocular component X X
Migraine chronic X X
Calcium antagonists X X X X
Enolism X X X X
Vitamin B12 X X
First grade family with migraine X X
Table 11. FSS on second infiltration training data.
Features selected FSS1 FSS2 FSS3 FSS4
Retroocular component X X
GON X X X X
Pneumopathy X X
Dermopathy X X
Vitamin B12 X X
1-Red. and Adv.Eff.clasif X X
an accuracy of 63.72% (baseline accuracy). Similar results were achieved in the 
second infiltration response prediction, where the “low” response represents 52.32% 
of all the dataset. These low accuracies may be a consequence of the large number of 
features in comparison with the reduced number of records in the medical data (52 
and 56 features vs 102 and 86 records for first and second infiltrations, respectively). 
Additionally, sensitivity and specificity values are less than or equal to 0.65. The 
exception is the IBk classifier for the first infiltration, whose sensitivity value is 0.78, 
which involves an excellent detection of patients who respond positively to treatment.
4.2.2. Feature subset selection
In Tables 10 and 11, the clinical features selected by methods of Table 4 are presented 
for the first and the second infiltrations, respectively.
For the first infiltration, calcium antagonists and enolism features were selected 
by the four evaluated FSS methods. For the second infiltration, only the previous 
greater occipital nerve block (GON) was taken into account by the four evaluated 
FSS methods. In addition to these, two features were selected in the first and the 
second infiltrations: the retroocular component and vitamin B12.
In the experiment of this section, only the features presented in the Tables 10
and 11 have been taken into account for building the prediction models of the first 
and second infiltration respectively. Table 12 presents the accuracy of classifiers 
when just using these features. A noticeable improvement in the second infiltration 
response prediction was achieved when using this approach. More specifically, the 
Naive Bayes algorithm achieved an accuracy of 70.31% in contrast to the 62.50% on.2018.e01043
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Classification algorithm
Naive Bayes
IBk
RIPPER
C4.5
Logistic
AdaBoostM1 (DecisionStump
Bagging (Random tree)
Bagging (C4.5)
LMT
NBTree
Random forest
Random tree
REPTree
DecisionStump
SVM
Means
Medians
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First infiltration Second infiltration
Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity
64.47% 0.67 0.56 70.31% 0.77 0.66
53.94% 0.60 0.31 42.18% 0.42 0.42
51.31% 0.58 0.17 68.75% 0.69 0.69
57.89% 0.61 0.33 60.93% 0.60 0.62
65.78% 0.68 0.59 62.50% 0.64 0.62
) 59.21% 0.62 0.40 62.50% 0.62 0.63
56.58% 0.62 0.38 64.06% 0.67 0.63
60.52% 0.63 0.46 54.68% 0.54 0.56
63.15% 0.65 0.54 54.68% 0.55 0.54
55.26% 0.59 0.14 59.37% 0.59 0.60
56.57% 0.62 0.38 65.62% 0.68 0.64
52.63% 0.59 0.29 59.37% 0.60 0.59
59.21% 0.62 0.38 65.62% 0.68 0.64
63.15% 0.63 0.67 56.25% 0.58 0.56
64.47% 0.65 0.63 67.18% 0.67 0.67
58.94% 0.62 0.42 60.93% 0.62 0.60
59.21% 0.62 0.38 62.50% 0.61 0.62
obtained by the NBTree classifier without applying the FSS method. Moreover, the 
sensitivity value of this classifier for the second infiltration is equal to 0.77, which 
involves an excellent detection of patients who respond positively to the treatment 
for such infiltration.
Despite this promising improvement, response predictions for the first infiltration 
were not significantly improved when comparing the baseline accuracy of 63.72% 
explained in Section 4.2.1. Furthermore, an accuracy of 70% for two class prediction 
is not close to the 91% accuracy obtained when using HIT6, as shown in Section 4.1. 
In addition, the sensitivity and specificity values are less than or equal to 0.67, which 
implies that false positive and false negatives are appearing with certain frequency.
4.2.3. Feature weighting with SA
As was mentioned in Section 3.3.3, SA is applied with the purpose of improving 
the representation of the numeric labels encoded by doctors (preprocessing). The 
number of iterations was defined as two million. Table 13 presents the accuracy 
of the classifier algorithms when applied together with the SA technique. Their 
accuracies improved significantly when using this technique. The best accuracy was 
achieved with random tree (≈85% and ≈86% for the first and the second infiltrations, 
respectively). The relevant medical factors found by the effective combination of SA 
and random tree are presented in Section 4.2.5. The sets of the best features found 
by FFS and the SA process are compared and discussed in Section 4.2.5 and 4.3.on.2018.e01043
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Table 13. Accuracy percenta
Classification algorithm
Naive Bayes
IBk
RIPPER
C4.5
Logistic
AdaBoostM1 (DecisionStump
Bagging (Random tree)
Bagging (C4.5)
LMT
NBTree
Random forest
Random tree
REPTree
DecisionStump
SVM
Means
Medians
22 https://doi.org/10.1016/j.heliy
2405-8440/© 2019 The Authors. Pubge of classifiers with simulated annealing.
First infiltration Second infiltration
Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity
64.98% 0.61 0.25 67.64% 0.63 0.68
75.00% 0.80 0.67 81.25% 0.83 0.80
67.11% 0.66 0.75 72.02% 0.72 0.75
61.24% 0.70 0.50 73.44% 0.68 0.81
67.11% 0.75 0.56 62.50% 0.61 0.65
) 65.79% 0.67 0.67 64.07% 0.68 0.62
75.00% 0.73 0.85 81.25% 0.83 0.80
61.85% 0.61 0.36 73.43% 0.75 0.72
65.79% 0.64 1.00 67.62% 0.70 0.68
60.53% 0.64 0.47 67.62% 0.70 0.68
80.77% 0.79 0.85 81.25% 0.83 0.80
84.61% 0.85 0.83 85.94% 0.82 0.90
67.11% 0.67 0.70 63.63% 0.64 0.63
65.79% 0.64 1.00 67.62% 0.69 0.68
75.00% 0.73 0.85 81.25% 0.83 0.80
69.18% 0.70 0.69 72.70% 0.73 0.73
67.11% 0.67 0.70 72.02% 0.70 0.72
Regarding the sensitivity and specificity, we can observe that some classifiers such as 
IBk, bagging with random tree, random forest, random tree and SVM possess values 
greater than 0.80. Of special consideration is the random tree algorithm, which also 
achieves a high accuracy. Given their high sensitivity and specificity values we can 
conclude that these classifiers perform a good detection of positive and negative 
responses to treatment in both infiltrations.
On the basis of the results, we can observe that non-deterministic classifier
algorithms (random tree and random forest) combined with SA perform the best 
in Table 13 (an accuracy higher than 80%). Previous results (Tables 8, 9 and 12) 
show that the best classifiers were deterministic. Then we can conclude that SA 
becomes an important factor, as it helps to optimize non-deterministic algorithms. 
Looking for the lowest fitness, SA moves the solution within the search space to avoid 
being caught in a local minimum in non-convex problems [53], and this benefits the 
non-deterministic algorithms.
Looking more closely at the results of sensitivity and specificity values of Tables 9
and 12, we can see an overall improvement in the specificity of nearly all
classification methods because of the SA pre-processing. In general, those now 
correctly classified cases are female patients with chronic migraine without aura, 
no retroocular component, nausea and vomiting, less than 48 months of migraine 
time evolution, previous radiofrequency treatment, topiramate and at least two other 
preventives drugs tested before toxin and calcium antagonists.
With the purpose of statistically validating if the improvement in classification due to 
the FSS and SA methods is significant, the Kruskal-Wallis (non-parametric) test with on.2018.e01043
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2405-8440/© 2019 The Authors. PubFigure 3. Accuracies distribution for first and second infiltration under the methods used in Tables 9, 12
and 13.
Table 14. Nemenyi post-hoc test for accuracies of Tables 9, 12 and 13.
Pair-methods comparison First infiltration Second infiltration
Mean rank difference p Mean rank difference p
Baseline-FSS −8.50000 0.1588 −10.17857 0.0720
SA-FSS 15.03571 0.0034 13.39286 0.0108
SA-Baseline 23.53571 1.2 ⋅ 10−6 23.57143 1.1 ⋅ 10−6
two degrees of freedom was carried out between the accuracy values of Tables 9, 12
and 13 for both infiltrations. This test gave us the results of 𝑝 = 1.753 ⋅ 10−6 for the 
first infiltration and 𝑝 = 2.146 ⋅ 10−6 for the second infiltration. These values, being 
less than 0.05, guarantee us that there is a significant difference in the distributions 
of values among groups. The distribution of classification accuracy obtained under 
the baseline (classifiers without any improvement), FSS and SA methods used in 
Tables 9, 12 and 13 for both infiltrations are presented in Figure 3. Table 14 shows 
the results of the Nemenyi post-hoc test for detecting which pairs of methods are 
significantly different. According to this test, the classifiers improved with SA had 
a highly significant difference (𝑝 < 0.01) in comparison to baseline classifiers and 
when considering FSS. On the contrary, FSS-baseline difference is not significant 
(𝑝 > 0.05).
4.2.4. Clustering methods
In this section, several clustering methods were evaluated by considering the class 
attribute defined by Equation (2) in combination with the SA algorithm. Cluster 
methods use heuristic criteria that seek to group patient records that contain the 
maximum closeness between them (Section 3.4.2). The number of clusters was 
established as two. This number was decided in order to cover the two values that 
take the class attribute to predict (high-low). The number of iterations that were on.2018.e01043
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2405-8440/© 2019 The Authors. PubTable 15. Accuracies of clustering algorithms when using 
simulated annealing.
Algorithm First infiltration Second infiltration
Meta-Cluster 80.77% 81.82%
EM 73.08% 77.28%
k-means 65.38% 81.82%
Farthest-First 88.47% 63.64%
executed to optimize the weights of features by SA was established in one million. As 
in the previous tests, clinical data belonging to the first and second infiltrations were 
taken into account. Table 15 shows the accuracy percentages for the four clustering 
methods described in Section 3.4.2. The farthest-first clustering method achieves 
the highest accuracy (88.47%) for the first infiltration. This prediction is better than 
the one obtained when using the random tree and SA combination for the same 
infiltration. Nevertheless, in general we have observed that this method does not 
obtain a big accuracy difference as random tree and SA combination. Supervised 
clustering may have achieved better accuracies than traditional clustering for the 
first infiltration, because the dataset has a high probability density with respect to a 
single class in that infiltration [43].
4.2.5. Consensus model
Section 3.5 discusses the importance of studying a consensus model with the 
prediction models built for the first and the second infiltration of the treatment. With 
our medical datasets, the random tree and SA combination has proved to be the best 
classifier for both infiltrations. We have induced many random tree models instead of 
clustering algorithms or random forest. This decision was taken because the models 
generated by clustering methods and by random forest are difficult to interpret in 
terms of relevant features. Moreover, only the most frequent features for each level 
of the studied models were taken into account. An important point to emphasize 
is that the ensemble tree obtained is not intended to be a prediction model of the 
treatment response for each infiltration. On the contrary, this allows us to know the 
most frequent clinical features and the relations that appear in the majority of the 
prediction models selected (only prediction models with the highest accuracies).
Many random trees were induced by the resampling method (using k-fold cross 
validation with k=10) with the SA optimization (used for the experiments in 
Section 4.2.3). These relevant features are contrasted with the important features 
obtained when using the FSS methodology in Section 4.2.2. The prediction models 
selected for induction were the models that achieved an accuracy of 84.61% and 
85.94% for the first and the second infiltrations, respectively. 5000 prediction models 
for each infiltration were generated from 50 SA weighted feature vectors, which on.2018.e01043
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random trees on the first infiltration.
Feature Frequency
GPT 1690
Hemoglobin 1056
Emergency days by month 668
Migraine days by month 516
History of migraine status 500
Vitamin B12 482
Creatinine 464
HTA 350
Platelets 310
Onset age of toxin treatment 300
Serum iron 300
Calcium antagonists 300
Headache days by month 248
Gastropathy 248
Radiofrequency Treatment 230
Urea 230
Enolism 222
GOT 184
GGT 182
Analgesics abuse 176
Retroocular component 168
Catamenial 120
Neuromodulator 114
Unilateral pain 112
Triptan days by month 110
Local painful pressure of greater occipital nerve (GON) 100
Chronic migraine 94
Nausea(Vomiting) 92
Folic acid 90
Tricyclic antidepressants 70
Migraine type 54
First grade family with migraine 50
Oral Preventive Treatment 42
Betablockers (B-blocker) 42
Concomitant antihypertensive treatment 28
Alkaline phosphatase 18
Migraine evolution time 18
Analgesic days by month 12
Symptomatic treatment 10
makes it possible to achieve the highest accuracies for both infiltrations. Regarding 
the root vertex of the ensemble tree, the 0.99 quantile was applied as the t value. 
Taking into account Table 16, this value was equal to 1449.08 for the first infiltration 
(t = 1552.56 for the second infiltration). In this way, GPT was selected as the root of 
the consensus tree for the first infiltration because of its high frequency (1690 times). 
In a similar way, t was defined as the 0.9 quantile from the empirical edge frequency 
distribution of the other levels of the ensemble tree for both infiltrations.
Figures 4 and 5 present the most frequent clinical features for both infiltrations. 
An important aspect to note is that we have defined the 𝐿𝑚𝑎𝑥 value as 3 for both 
infiltrations. This value was established by considering the comprehension of the on.2018.e01043
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2405-8440/© 2019 The Authors. PubFigure 4. Consensus tree using random tree models for the first infiltration.
Figure 5. Consensus tree using random tree models for the second infiltration.
resultant consensus tree as a primordial criterion. Higher values of this parameter 
would allow us to see more features, but comprehension could decrease when 
contrasting these features with those obtained with the FSS method. In this sense, a 
consensus tree with a low number of leaves is more understandable. Features were 
filled with different box colors that indicate different levels of the tree (purple, blue 
and black for levels 1, 2 and 3 of the tree). In addition to this, red circles indicate the 
features that were selected when performing the FSS methods presented in Tables 10
and 11 for the first and the second infiltrations, respectively. With this analysis, the 
sum of the frequency of edges will not necessarily be equal to the frequency of their 
parent nodes because not all edges are represented in the consensus tree, but only 
the edges that exceeded the t value.
According to these consensus trees, the most important factors that influence the 
prediction of the treatment response to BoNT-A for the first infiltration are GPT, 
drugs tested before toxin, migraine type, chronic migraine time evolution, first grade 
family with migraine and others. For the second infiltration, the factors are GON, on.2018.e01043
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retroocular component and analgesic days by month. Although it is true that in the 
experiments of the previous sections it has been shown that SA obtains a better 
accuracy than the use of FSS, we can point out that they select similar features 
with respect to the selected by FSS. For example: first grade family with migraine, 
enolism, onset of toxin administration and calcium antagonists were indicated by 
both methods as relevant features for the first infiltration while for the second were 
the GON and the retroocular component.
4.3. Medical discussion
The transformation of episodic migraine into chronic migraine occurs over months 
or years and involves atypical pain modulation and central sensitization triggered 
by repetitive inputs from sensitized peripheral sensory neurons [54]. The exact 
analgesic mechanism of action of BoNT-A is only partially known. The main 
hypothesis is that the toxin exerts its antinociceptive action inhibiting peripheral 
sensitization. BoNT-A lowers neuropeptide and neurotransmitter release from 
peripheral sensory neurons, thereby indirectly reducing central sensitization, the 
hallmark of chronic migraine [55,56].
The aforementioned data suggest that the pharmacological response to BoNT-A 
might be better when the migraine headache is “trigeminal” in pain location and 
corresponds to reflex trigeminal-autonomic activation [56,57]. As a consequence, 
BoNT-A action may be more effective in migraineurs who overactivate peripheral 
trigeminal endings during the attack, and such patients may be identified by means of 
easily obtainable patient-reported clinical findings, such as pain location or direction 
(unilateral, implosive-retroocular), the presence of cranial autonomic symptoms 
(allodynia) and cortical spreading depression signs (aura) [56]. Other data such 
as the response to anesthetic block of the greater occipital nerve (GON) or its 
local painful pressure (positive palpation) might suggest the same. Many authors 
believe that a therapy which blocks peripheral transmission of pain signals from 
extracranial areas prior to central sensitization will successfully disrupt migraine 
headache propagation [25,58,59].
In our results, the GON and the retroocular component were also selected as relevant 
features when building our most accurate prediction models. Therefore, we can 
conclude that the relevant features extracted by FSS and the consensus random trees 
are coherent with respect to the medical literature.on.2018.e01043
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This study assesses the application of data mining techniques to the prediction of 
BoNT-A treatment efficiency for migraine patients. In this work, two methodologies 
are presented. The first is based on the perceptional HIT6 value, which is not 
frequently found in our clinical databases. In order to overcome this limitation, a 
second methodology based on more widely available clinical features is presented. 
A preprocessing strategy based on simulated annealing is proposed to select the best 
way to represent the information in terms of prediction accuracy. The combination of 
simulated annealing and the random tree algorithm allows us to obtain an accuracy 
of 85% without considering the rarely found HIT6 value.
In addition, relevant clinical features extracted when using FSS and consensus 
random trees have been presented. Features such as GON and the retroocular 
component have also been described as important clinical features to consider for 
migraine treatment in the medical literature. This knowledge allows us to conclude 
that the features considered in our prediction models are coherent with respect to the 
medical literature.
In the future, the use of bootstrapping-based techniques to obtain a predictive 
model from the random sampling generated will be contempled. In addition, some 
optimizations need to be done in order to increase the prediction accuracy.
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